Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Application, End-User

Description

List of Tables

The Global Patient-Derived Xenograft/PDX Model Market is forecasted to grow significantly, with a projected USD 222.26 million in 2023 at a CAGR of 14.47% and expected to reach a staggering USD 574.99 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Patient-Derived Xenograft/PDX Model Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Patient-Derived Xenograft/PDX Model Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Mice Models and Rat Models. The Mice Models is projected to witness significant market share during forecast period.

Based on Tumor Type, market is studied across Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models, Respiratory Tumor Models, and Urological Tumor Models. The Gynecological Tumor Models is projected to witness significant market share during forecast period.

Based on Application, market is studied across Basic Cancer Research, Biomarker Analysis, and Preclinical Drug Development. The Basic Cancer Research is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Academic & Research Institutions, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutions is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Patient-Derived Xenograft/PDX Model Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Patient-Derived Xenograft/PDX Model Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Patient-Derived Xenograft/PDX Model Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Patient-Derived Xenograft/PDX Model Market?

4. What is the competitive strategic window for opportunities in the Global Patient-Derived Xenograft/PDX Model Market?

5. What are the technology trends and regulatory frameworks in the Global Patient-Derived Xenograft/PDX Model Market?

6. What is the market share of the leading vendors in the Global Patient-Derived Xenograft/PDX Model Market?

7. What modes and strategic moves are considered suitable for entering the Global Patient-Derived Xenograft/PDX Model Market?

Product Code: MRR-FF1601152761

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Patient-Derived Xenograft/PDX Model Market, by Type, 2022 vs 2030
4.3. Patient-Derived Xenograft/PDX Model Market, by Tumor Type, 2022 vs 2030
4.4. Patient-Derived Xenograft/PDX Model Market, by Application, 2022 vs 2030
4.5. Patient-Derived Xenograft/PDX Model Market, by End-User, 2022 vs 2030
4.6. Patient-Derived Xenograft/PDX Model Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing demand for personalized medicine
  - 5.1.1.2. Oncology and preclinical development
  - 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
- 5.1.2. Restraints
  - 5.1.2.1. High cost of personalized PDX model
- 5.1.3. Opportunities
  - 5.1.3.1. Rising demand for humanized PDX Model
  - 5.1.3.2. Growth in pharma R&D
- 5.1.4. Challenges
  - 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Patient-Derived Xenograft/PDX Model Market, by Type

6.1. Introduction
6.2. Mice Models
6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

7.1. Introduction
7.2. Gastrointestinal Tumor Models
7.3. Gynecological Tumor Models
7.4. Hematological Tumor Models
7.5. Respiratory Tumor Models
7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

8.1. Introduction
8.2. Basic Cancer Research
8.3. Biomarker Analysis
8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutions
9.3. Contract Research Organizations
9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing